Antibody positron emission tomography imaging in anticancer drug development von Lamberts, Laetitia E, Williams, Simon P, Terwisscha van Scheltinga, Anton G T, Lub-de Hooge, Marjolijn N, Schröder, Carolien P, Gietema, Jourik A, Brouwers, Adrienne H, de Vries, Elisabeth G E

Volltext

Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study von Lamberts, Laetitia E, Koch, Maximillian, de Jong, Johannes S, Adams, Arthur L L, Glatz, Jürgen, Kranendonk, Mariëtte E G, Terwisscha van Scheltinga, Anton G T, Jansen, Liesbeth, de Vries, Jakob, Lub-de Hooge, Marjolijn N, Schröder, Carolien P, Jorritsma-Smit, Annelies, Linssen, Matthijs D, de Boer, Esther, van der Vegt, Bert, Nagengast, Wouter B, Elias, Sjoerd G, Oliveira, Sabrina, Witkamp, Arjen J, Mali, Willem P Th M, Van der Wall, Elsken, van Diest, Paul J, de Vries, Elisabeth G E, Ntziachristos, Vasilis, van Dam, Gooitzen M

Volltext

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer von Weekes, Colin D, Lamberts, Laetitia E, Borad, Mitesh J, Voortman, Johannes, McWilliams, Robert R, Diamond, Jennifer R, de Vries, Elisabeth G E, Verheul, Henk M, Lieu, Christopher H, Kim, George P, Wang, Yulei, Scales, Suzie J, Samineni, Divya, Brunstein, Flavia, Choi, YounJeong, Maslyar, Daniel J, Colon-Otero, Gerardo

Volltext

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment von Lamberts, Laetitia E, Menke-van der Houven van Oordt, Catharina W, ter Weele, Eva J, Bensch, Frederike, Smeenk, Michiel M, Voortman, Johannes, Hoekstra, Otto S, Williams, Simon P, Fine, Bernard M, Maslyar, Daniel, de Jong, Johan R, Gietema, Jourik A, Schröder, Carolien P, Bongaerts, Alphons H H, Lub-de Hooge, Marjolijn N, Verheul, Henk M W, Sanabria Bohorquez, Sandra M, Glaudemans, Andor W J M, de Vries, Elisabeth G E

Volltext

HER3, serious partner in crime. Therapeutic approaches and potential biomarkers for effect of HER3-targeting von KOL, Arjan, VAN SCHELTINGA, Anton G. T. Terwisscha, TIMMER-BOSSCHA, Hetty, LAMBERTS, Laetitia E, BENSCH, Frederike, DE VRIES, Elisabeth G. E, SCHRÖDER, Carolina P

Volltext

Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer von Koch, Maximilian, de Jong, Johannes S, Glatz, Jürgen, Symvoulidis, Panagiotis, Lamberts, Laetitia E, Adams, Arthur L L, Kranendonk, Mariëtte E G, Terwisscha van Scheltinga, Anton G T, Aichler, Michaela, Jansen, Liesbeth, de Vries, Jakob, Lub-de Hooge, Marjolijn N, Schröder, Carolien P, Jorritsma-Smit, Annelies, Linssen, Matthijs D, de Boer, Esther, van der Vegt, Bert, Nagengast, Wouter B, Elias, Sjoerd G, Oliveira, Sabrina, Witkamp, Arjen J, Mali, Willem P T M, Van der Wall, Elsken, Garcia-Allende, P Beatriz, van Diest, Paul J, de Vries, Elisabeth G E, Walch, Axel, van Dam, Gooitzen M, Ntziachristos, Vasilis

Volltext

Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9 von Janse, Marcel, Lamberts, Laetitia E., Franke, Lude, Raychaudhuri, Soumya, Ellinghaus, Eva, Muri Boberg, Kirsten, Melum, Espen, Folseraas, Trine, Schrumpf, Erik, Bergquist, Annika, Björnsson, Einar, Fu, Jingyuan, Jan Westra, Harm, Groen, Harry J.M., Fehrmann, Rudolf S.N., Smolonska, Joanna, van den Berg, Leonard H., Ophoff, Roel A., Porte, Robert J., Weismüller, Tobias J., Wedemeyer, Jochen, Schramm, Christoph, Sterneck, Martina, Günther, Rainer, Braun, Felix, Vermeire, Severine, Henckaerts, Liesbet, Wijmenga, Cisca, Ponsioen, Cyriel Y., Schreiber, Stefan, Karlsen, Tom H., Franke, Andre, Weersma, Rinse K.

Volltext

IBD is associated with an increase in carcinoma in PSC irrespective of the presence of dominant bile duct stenosis von Janse, Marcel, Lamberts, Laetitia E, Verdonk, Robert C, Weersma, Rinse K

Volltext

Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types von Lamberts, Laetitia E, de Groot, Derk Jan A, Bense, Rico D, de Vries, Elisabeth G E, Fehrmann, Rudolf S N

Volltext

89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors von Bensch, Frederike, Lamberts, Laetitia E., Smeenk, Michaël M., Jorritsma-Smit, Annelies, Lub-de Hooge, Marjolijn N., Terwisscha van Scheltinga, Anton G.T., de Jong, Johan R., Gietema, Jourik A., Schröder, Carolien P., Thomas, Marlene, Jacob, Wolfgang, Abiraj, Keelara, Adessi, Celine, Meneses-Lorente, Georgina, James, Ian, Weisser, Martin, Brouwers, Adrienne H., de Vries, Elisabeth G.E.

Volltext

Molecular imaging for monitoring treatment response in breast cancer patients von Bensch, Frederike, van Kruchten, Michel, Lamberts, Laetitia E., Schröder, Carolien P., Hospers, Geke A.P., Brouwers, Adrienne H., van Vugt, Marcel A.T.M., de Vries, Elisabeth G.E.

Volltext

Immune-mediated diseases in primary sclerosing cholangitis von Lamberts, Laetitia E, Janse, Marcel, Haagsma, Elizabeth B, van den Berg, Arie P, Weersma, Rinse K

Volltext

Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts von ter Weele, Eva J, Terwisscha van Scheltinga, Anton G T, Kosterink, Jos G W, Pot, Linda, Vedelaar, Silke R, Lamberts, Laetitia E, Williams, Simon P, Lub-de Hooge, Marjolijn N, de Vries, Elisabeth G E

Volltext

Immune-Mediated Diseases in Primary Sclerosing Cholangitis von Lamberts, Laetitia E, Janse, Marcel, Haagsma, Elizabeth B, Van den Berg, Arie P, Weersma, Rinse K

Volltext

Three Genetic Susceptibility Loci Indicate a Role for IL2, REL and CARD9 in Primary Sclerosing Cholangitis von Janse, Marcel, Lamberts, Laetitia E, Franke, Lude, Raychaudhuri, Soumya, Ellinghaus, Eva, Boberg, Kirsten Muri, Melum, Espen, Schrumpf, Erik, Bergquist, Annika, Bjornsson, Einar, Porte, Robert J, Weismüller, Tobias J, Wedemeyer, Jochen, Schramm, Christoph, Sterneck, Martina, Günther, Rainer, Braun, Felix, Vermeire, Severine, Henckaerts, Liesbet, Wijmenga, Cisca, Ponsioen, Cyriel, Schreiber, Stefan, Karlsen, Tom H, Franke, Andre, Weersma, Rinse K

Volltext

Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study von Lamberts, Laetitia E, Koch, Maximillian, de Jong, Johannes S, Adams, Arthur, Glatz, Juergen, Kranendonk, Marriette E G, Terwisscha van Scheltinga, Anton G T, Jansen, Liesbeth, de Vries, Jakob, Lub-de Hooge, Marjolijn N, Schroder, Carolien P, Jorritsma-Smit, Annelies, Linssen, Matthijs D, de Boer, Esther, van der Vegt, Bert, Nagengast, Wouter B, Elias, Sjoerd G, Oliveira, Sabrina, Witkamp, Arjen, Mali, Willem P Th M, van der Wall, Elsken, Van Diest, Paul J, de Vries, Elisabeth G, Ntziachristos, Vasilis, van Dam, Gooitzen M

Volltext

HER3, serious partner in crime von Kol, Arjan, Terwisscha van Scheltinga, Anton G.T., Timmer-Bosscha, Hetty, Lamberts, Laetitia E., Bensch, Frederike, de Vries, Elisabeth G.E., Schröder, Carolina P.

Volltext

89 Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment of solid tumor patients von Bensch, Frederike, Lamberts, Laetitia E., Smeenk, Michiel M., Jorritsma-Smit, Annelies, Lub-de Hooge, Marjolijn N., Terwisscha van Scheltinga, Anton G.T., de Jong, Johan R., Gietema, Jourik A., Schroder, Carolina Pia, Thomas, Marlene, Jacob, Wolfgang, Abiraj, Keelara, Adessi, Celine, Meneses-Lorente, Georgina, James, Ian, Weisser, Martin, Brouwers, Adrienne H., De Vries, Elisabeth

Volltext

Threshold analysis and biodistribution of fluorescently labeled bevacizumab in human breast cancer von Koch, Maximillian, de Jong, Johannes S, Glatz, Jürgen, Symvoulidis, Panagiotis, Lamberts, Laetitia E, Adams, Arthur, Kranendonk, Mariëtte E G, Terwisscha van Scheltinga, Anton G T, Aichler, Michaela, Jansen, Liesbeth, de Vries, Jakob, Lub-de Hooge, Marjolijn N, Schröder, Carolina P, Jorritsma-Smit, Annelies, Linssen, Matthijs D, de Boer, Esther, van der Vegt, Bert, Nagengast, Wouter B, Elias, Sjoerd G, Oliveira, Sabrina, Witkamp, Arjen, Mali, Willem P Th M, van der Wall, Elsken, Garcia-Allende, Beatriz P, Van Diest, Paul J, de Vries, Elisabeth G, Walch, Axel, van Dam, Gooitzen M, Ntziachristos, Vasilis

Volltext

PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC) von Gebhart, Geraldine, Lamberts, Laetitia E., Garcia, Camilo, Ameye, Lieveke, Stroobants, Sigrid, Huizing, Manon, Aftimos, Philippe G., Tol, Jolien, Oyen, Wim J.G., Wimana, Zena, Dongen, G.A.M.S. van, Hoekstra, Otto S., Schroder, Carolien P., Gaye, Julie, Menke, Catharina Wilhelmina, Guiot, Thomas, Brouwers, Adrienne H., Awada, Ahmad, de Vries, Elisabeth G. E., Flamen, Patrick

Volltext